文献速递肝病

接受熊去氧胆酸治疗的原发性胆汁性胆管炎患者中碱性磷酸酶与GLOBE评分对无肝移植生存的影响

Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
PubMed 文献 · Aliment Pharmacol Ther · 2022-09-22

在Global PBC队列中,按GLOBE评分分组评估UDCA治疗1年后ALP与无肝移植生存的关联。GLOBE评分正常者中ALP与肝移植/死亡风险相关(aHR 1.31,95%CI 1.003-1.72,p=0.048),ALP正常者10年无肝移植生存优于匹配人群。

要点

  • GLOBE评分正常者中,UDCA治疗1年后ALP与肝移植/死亡风险相关(aHR 1.31)。
  • GLOBE评分正常且ALP正常者10年无肝移植生存优于匹配人群。
  • GLOBE评分升高者中,ALP仅与<50岁患者的肝移植/死亡风险相关(aHR 1.38)。

核心结论

  • GLOBE评分正常的PBC患者,ALP正常时无肝移植生存最优,且优于匹配一般人群。
  • 尽管总体预后良好,ALP升高可能仍提示需要附加治疗。

研究设计与样本

  • 在Global PBC队列中,按GLOBE评分正常或升高分层,评估UDCA治疗1年后ALP与肝移植/死亡风险的关联。
  • GLOBE评分正常组2729例,GLOBE评分升高组1045例;无肝移植生存与匹配一般人群比较。

主要发现

  • GLOBE评分正常组中,ALP与肝移植/死亡风险相关(aHR 1.31,95% CI 1.003-1.72,p=0.048)。
  • GLOBE评分正常且ALP>2.0×ULN者,<50岁10年无肝移植生存94.0%(95% CI 90.1-97.9),显著低于匹配人群(p=0.040)。
  • GLOBE评分正常且ALP>2.0×ULN者,≥50岁10年无肝移植生存82.6%(95% CI 76.5-88.7),与匹配人群相似(p=0.736)。
  • GLOBE评分正常且ALP正常者,≥50岁10年无肝移植生存90.8%(95% CI 87.7-93.9),显著高于匹配人群(p=0.022)。
  • GLOBE评分升高组中,ALP仅与<50岁患者的肝移植/死亡风险相关(aHR 1.38,95% CI 1.06-1.81,p=0.016)。

临床怎么用

  • GLOBE评分正常的PBC患者,UDCA治疗1年后ALP正常提示无肝移植生存最优。
  • GLOBE评分正常但ALP升高者,尤其<50岁,无肝移植生存低于匹配人群,作者认为ALP升高可能仍提示需要附加治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels. AIM: To assess the association between ALP and liver transplantation (LT)-free survival according to the GLOBE score METHODS: Among patients with a normal or elevated GLOBE score in the Global PBC cohort, the association between ALP after 1 year of UDCA and the risk of LT/death was assessed. The LT-free survival was compared with that of a matched general population. RESULTS: After 1 year of UDCA, ALP was associated with the risk of LT/death (aHR 1.31, 95% CI 1.003-1.72, p = 0.048) among 2729 patients with a normal GLOBE score. The 10-year LT-free survival among these patients with an ALP >2.0 × ULN was 94.0% (95% CI 90.1-97.9) for those <50 years, and 82.6% (95% CI 76.5-88.7) for those ≥50 years, which was significantly lower (p = 0.040) and similar (p = 0.736) to that of the matched population, respectively. The 10-year LT-free survival in patients ≥50 years with normal GLOBE score and normal ALP (90.8%, 95% CI 87.7-93.9) was significantly higher (p = 0.022) than the matched population. Among 1045 patients with an elevated GLOBE score, ALP was associated with LT/death only in those <50 years (aHR 1.38, 95% CI 1.06-1.81, p = 0.016). CONCLUSION: The LT-free survival of patients with PBC with a normal GLOBE score is optimal in case of normal ALP levels, also in relation to the general population. Despite their generally favourable prognosis, an elevated ALP level may still indicate a need for add-on therapy. xxx[Image: see text]

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. de Veer RC, Harms MH, Corpechot C, et al. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. Aliment Pharmacol Ther. 2022. PMID: 36138566. doi:10.1111/apt.17226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。